Contact
searchSearch
HMP Global
Login

GPRC5D Biological Pathways Reviews

Videos

Sundar Jagannath, MD, Mount Sinai
Videos
Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent
02/23/2023
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides...
02/23/2023
Oncology
Dan Vogl, MD, University of Pennsylvania
Videos
Bispecific T-Cell Engagers and Novel Approaches for the Treatment of Multiple Myeloma
02/23/2023
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options...
02/23/2023
Oncology
Faith Davies, MD
Videos
What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?
02/16/2023
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an...
02/16/2023
Oncology
Stefania Napolitano, MD, PhD
Videos
ctDNA-Guided Selection Optimizes Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses results from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Stefania Napolitano, MD, PhD
Videos
Anti-EGFR Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/29/2026
Stefania Napolitano, MD, PhD
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD, discusses background and methods from the phase 2 CAVE-2 GOIM trial evaluating anti-EGFR rechallenge strategies in patients with RAS/BRAF wild-type metastatic colorectal cancer selected using ctDNA profiling.
Stefania Napolitano, MD, PhD,...
01/29/2026
Oncology
Eric Mastrolonardo, MD
Videos
Pathologic Response After Neoadjuvant Immunotherapy Correlates With Disease-Free Survival in Head and Neck Cancer
01/26/2026
Eric Mastrolonardo, MD
Eric Mastrolonardo, MD, discusses findings from a systematic review and meta-analysis evaluating whether pathologic treatment response after neoadjuvant immune checkpoint inhibition is associated with survival outcomes in resectable mucosal...
Eric Mastrolonardo, MD, discusses findings from a systematic review and meta-analysis evaluating whether pathologic treatment response after neoadjuvant immune checkpoint inhibition is associated with survival outcomes in resectable mucosal...
Eric Mastrolonardo, MD,...
01/26/2026
Oncology
Stephen Lam Chan, MD
Conference Coverage
Adjuvant Pembrolizumab Fails to Improve Recurrence-Free Survival in Hepatocellular Carcinoma
01/26/2026
Stephen Lam Chan, MD
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses results from the phase 3 KEYNOTE-937 trial which demonstrated that adjuvant pembrolizumab did not significantly improve recurrence-free survival following curative-intent resection or local ablation for...
Stephen Lam Chan, MD, discusses...
01/26/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Time and Travel Impact of CAR T-Cell vs Bispecific Antibody Therapy for Patients With R/R DLBCL: Real-World Analysis
01/26/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS, reported that axi-cel was associated with lower time and travel burden than bispecific antibodies in the third-line or later setting for patients with relapsed/refractory diffuse large b-cell lymphoma.
Olalekan Oluwole, MD, MBBS,...
01/26/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Jessica Walchonski, PA-C, MMS
Conference Coverage
Exploring Key Advances and Emerging Therapies in Gynecologic Oncology
01/23/2026
Jessica Walchonski, PA-C, MMS
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS, reviewed recent advances in gynecologic oncology, highlighting new targeted and immunotherapy options for ovarian cancer and evolving strategies for endometrial cancer at the 2025 Oncology Learning Network APP...
Jessica Walchonski, PA-C, MMS,...
01/23/2026
Oncology Learning Network APP Institute
Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
OLN

GPRC5D

ALIASES

G-protein coupled receptor family C group 5 member D

References

G protein-coupled receptor class C group 5 member D (GPRC5D) is a gene expressed in the hair follicle and malignant bone marrow plasma cells.1 G protein-coupled receptor proteins are cell surface receptors located in the plasma membrane. Activation of the protein occurs when it binds to an external signaling molecule, which causes a conformational change and triggers an interaction between the protein and an available G protein.2

Understanding the Role of GPRC5D

Expression Percentages per Cancer Type

Multiple Myeloma
88%

Resources

News
GPRC5D-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
03/23/2023
Amber Denham
Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.
Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.
Phase 1 results from the POLARIS...
03/23/2023
Oncology
News
Promising Clinical Efficacy for GPRC5D-Targeting CAR-T Cell Therapy in R/R Multiple Myeloma
03/23/2023
Amber Denham
GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.
GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.
GPRC5D-targeting CAR-T cell...
03/23/2023
Oncology
News
Talquetamab Shows Promise as Novel Agent for Patients With Multiple Myeloma
06/20/2022
Yvette C. Terrie, BS Pharm, RPh
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel...
06/20/2022
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

Podcasts

Podcasts
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG)
01/02/2026
Cassie Kline, MD, MAS
Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...
Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...
Dr Cassie Klein presents a...
01/02/2026
Oncology
Podcasts
Case Files: Axatilimab Use in a Patient With Chronic Graft-Versus-Host-Disease 
09/16/2025
Benjamin Watkins, MD
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using...
09/16/2025
Oncology
Podcasts
Navigating Second-Line Decisions: Real-World Management of Chronic Graft-Versus-Host Disease (GVHD)
09/16/2025
Shernan Holtan, MD
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results...
09/16/2025
Oncology
Podcasts
From Steroids to Second-Line Therapy—What Drives the Move? 
09/16/2025
Betty Hamilton, MD
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what...
09/16/2025
Oncology
Podcasts
Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment 
09/16/2025
Yi-Bin Chen, MD
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating...
09/16/2025
Oncology
Podcasts
Podcast: Selecting Second-Line Therapy for Relapsing/Remitting Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the...
05/13/2025
Oncology
Podcasts
Podcast: Targeted Therapies for Relapsing/Remitting Pediatric Low-Grade Glioma (R/R pLGG)
05/13/2025
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the...
05/13/2025
Oncology
Dr Hwang
Podcasts
Podcast: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the...
05/13/2025
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology

Interactive

Quiz
Quiz: Where is the GPRC5D Gene Expressed?
03/23/2023
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene...
03/23/2023
Oncology
Quiz
Quiz: Principles Behind Choosing Optimal Therapeutic Agent Combinations for Patients With MM
03/20/2023
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies,...
03/20/2023
Oncology
Quiz
Berzosertib Plus Topotecan vs Topotecan Monotherapy for SCLC
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology
Quiz
Atezolizumab Plus FOLFIRINOX and Bevacizumab for dMMR/MSI-H mCRC
01/27/2026
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination of atezolizumab with FOLFIRINOX and bevacizumab significantly prolonged progression-free survival compared with atezolizumab monotherapy among patients with treatment-naive dMMR/MSI-H metastatic colorectal...
True or False: The combination...
01/27/2026
Oncology
Quiz
Exploring CSF-1-Targeted Therapies for TGCT
01/26/2026
True or false: Investigational agents such as pimicotinib and emactuzumab have shown encouraging activity in tenosynovial giant cell tumor (TGCT), with early data suggesting potentially higher response rates and improved safety profiles.
True or false: Investigational agents such as pimicotinib and emactuzumab have shown encouraging activity in tenosynovial giant cell tumor (TGCT), with early data suggesting potentially higher response rates and improved safety profiles.
True or false: Investigational...
01/26/2026
Oncology
Quiz
Evaluating Targeted Therapies in Glioblastoma
01/26/2026
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted therapies—including immune checkpoint inhibitors (ICIs) and mammalian target of rapamycin (mTOR) inhibitors—did not demonstrate improved survival in unselected glioblastoma populations, according to a systematic review...
True or false: Targeted...
01/26/2026
Oncology
Quiz
Rovadicitinib for Ruxolitinib-Resistant or Intolerant Myelofibrosis
01/14/2026
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The first-in-class oral JAK/ROCK inhibitor, rovadicitinib, did not demonstrate promising clinical responses or a favorable safety profile among patients with myelofibrosis who were relapsed/refractory or intolerant to prior...
True or False: The...
01/14/2026
Oncology
Quiz
CMS4 and Anti-EGFR Benefit in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/13/2026
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus molecular subtype 4 does not show potential utility as a predictive biomarker for improved outcomes with anti-epidermal growth factor receptor therapy among patients with RAS and BRAF wild-type metastatic colorectal...
True or False: Consensus...
01/13/2026
Oncology
Quiz
Eflornithine Plus Lomustine for Recurrent Grade 3 Astrocytoma
01/13/2026
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine combined with lomustine significantly prolonged both progression-free and overall survival in patients with recurrent IDH-mutant, grade 3 astrocytoma following prior radiotherapy and temozolomide, compared with...
True or false: Eflornithine...
01/13/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Quiz
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG): Pre-Content Quiz
01/02/2026
01/02/2026
Oncology
Quiz
Molecular Drivers of Pigmented Villonodular Synovitis
12/18/2025
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular...
12/18/2025
Oncology

GPRC5D Targeting Anticancer Drugs

GPRC5D is a promising immunotherapeutic target, particularly in patients with multiple myeloma. This table outlines therapies targeting GPRC5D in the pipeline.

Table icon
View Table
X

GPRC5D Targeting Anticancer Drugs in the Pipeline

Generic Drug Name

Potential Indications

Talquetamab1

A first-in-class investigational bispecific antibody targeting both GPRC5D and CD3 being evaluated for the treatment of patients with relapsed or refractory multiple myeloma.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use